

Date: - May 27, 2023

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400051

Sub: Statement of Deviation/Variation for Utilization of funds raised through Initial Public Offer for the half year ended on March 31, 2023.

Ref: Aristo Bio-Tech and Lifescience Limited (SYMBOL/ISIN-ARISTO/INE082101010)

Dear Sir/Madam,

With reference to captioned subject and pursuant to Regulation 32 (1) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, please find enclosed herewith statement of Deviation/variation in utilization of funds raised through Initial Public Offer for the half year ended on March 31, 2023.

We would hereby further inform you that the said statement is reviewed by the Audit Committee in its meeting held on Saturday, May 27, 2023.

Kindly take this information on your record.

For, Aristo Bio-Tech and Lifescience Limited

NARENDRA
SINGH BARHAT

Digitally signed by NARENDRA
SINGH BARHAT
Date: 2023.05.27 18:01:15 +05'30'

Narendra Singh Barhat
Chairman cum Managing Director
DIN: 00310306

Place: Vadodara

Encl; A/a

STATEMENT OF DEVIATION / VARIATION IN UTILISATION OF FUNDS RAISED THROUGH PUBLIC ISSUE, FOR THE HALF YEAR ENDED MARCH 31, 2023.

Name of Listed Entity	Aristo Bio-Tech and Lifescience Limited
Mode of Fund Raising	Public Issue-SME IPO
Date of Raising Funds	January 25, 2023 (Trading Approval Dated January 27, 2023 received from NSE) (Allotment Made on January 25, 2023)
Amount Raised (in Rs. Crores)	Fresh Issue: Rs. 13.05/- Crores i.e. (18,12,800 Equity shares at a cash price of Rs. 72 per equity Shares (Including a Share Premium of Rs. 62/- Per Equity Share)
Report filed for Half year ended	March 31, 2023
Monitoring Agency	Not Applicable
Monitoring Agency Name, if Applicable	Not Applicable
Is there a Deviation/Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of Shareholder Approval	Not Applicable
Explanation for the Deviation/Variation	Not Applicable
Comments of the Audit Committee after review	The Proceeds from IPO utilized for the Objects for which it was raised
Comments of the auditors, if any	No Comments

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation*	Modified Allocation, if any	Funds Utilised till March 31, 2023.	Amount of Deviation /Variation for quarter according to applicable object	Remarks, if any
1. To Meet Working Capital Requirements	Not Applicable	Rs. 9.35 Crores	Not Applicable	1. To Meet Incremental Working Capital Requirements- Rs. 9.35 Crores	-	Not Applicable
2. General Corporate Expenses.		Rs. 2.50 Crores		2. General Corporate Purpose.- Rs.		
3. Public						

Issue Expenses		Rs.1.20 Crores		2.50 Crores 3. Public Issue Expenses- Rs.1.20 Crores		
Deviation or variation could mean:						
(a) Deviation in the objects or purpose for which the funds have been raised or						
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or						
(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.						

For, Aristo Bio-Tech and Lifescience Limited

NARENDRA
SINGH BARHAT

Digitally signed by NARENDRA
SINGH BARHAT
Date: 2023.05.27 18:01:39
+05'30'

Narendra Singh Barhat
Chairman cum Managing Director
DIN: 00310306